Dansin E, Wallaert B, Rémy-Jardin M, Perez T, Hatron P Y, Rémy J, Tonnel A B
Service de Pneumo-immunoallergologie, Hôpital Calmette, Lille.
Rev Mal Respir. 1991;8(6):551-8.
Systemic diseases such as scleroderma (ScI), rheumatoid polyarthritis (PR), Gougerot-Sjögren Syndrome (GS) have a well known propensity for the lungs. Previous studies have shown evidence of disturbed alveolar cell repair as evidence of a sub-clinical alveolitis. The significance of such cases of latent alveolitis remains to be specified. To determine if latent alveolitis was associated with interstitial chest disease which was undetectable by chest X-ray, 36 consecutive patients had an BAL and a high resolution computered tomographic examination (HRTC) (Scl: n = 21; PR: n = 9; GS: n = 6). The patients had normal respiratory function and chest X-ray was normal. Our results showed 17 out of 36 (47%) with a latent alveolitis (the percentage of lymphocytes and of alveolar polymorpho-nuclear neutrophils was superior or equal to 18 and 4% respectively) (Scl: 12/21; PR: 1/9; GS: 4/6). In the cases of scleroderma a neutrophil alveolitis was predominant (9/12) and was associated in 2 cases with a honeycomb lung and evidence of fibrotic lesions using TDM-HR. Those examinations using HRTC which were normal were equally associated with a latent alveolitis (Scl: 6/12; PR: 1/6; GR: 4/5). These results suggest that the alveolitis can preceed the anatomical damages. These results need to be confirmed in a larger series and the value of early treatment should be evaluated.
系统性疾病,如硬皮病(ScI)、类风湿性多关节炎(PR)、舍格伦综合征(GS),对肺部有众所周知的易感性。先前的研究已显示肺泡细胞修复紊乱的证据,作为亚临床肺泡炎的证据。这种潜伏性肺泡炎病例的意义仍有待明确。为了确定潜伏性肺泡炎是否与胸部X线检查无法检测到的间质性肺病有关,连续36例患者进行了支气管肺泡灌洗(BAL)和高分辨率计算机断层扫描检查(HRTC)(硬皮病:n = 21;类风湿性多关节炎:n = 9;舍格伦综合征:n = 6)。患者呼吸功能正常,胸部X线检查正常。我们的结果显示,36例中有17例(47%)存在潜伏性肺泡炎(淋巴细胞和肺泡多形核中性粒细胞的百分比分别高于或等于18%和4%)(硬皮病:12/21;类风湿性多关节炎:1/9;舍格伦综合征:4/6)。在硬皮病病例中,中性粒细胞肺泡炎占主导(9/12),2例伴有蜂窝肺,并使用TDM-HR显示有纤维化病变的证据。那些HRTC检查正常的病例同样与潜伏性肺泡炎有关(硬皮病:6/12;类风湿性多关节炎:1/6;舍格伦综合征:4/5)。这些结果表明肺泡炎可能先于解剖学损伤出现。这些结果需要在更大的系列研究中得到证实,并且应评估早期治疗的价值。